RT Conference Proceedings
T1 Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
A1 Neukam, Karin
A1 Espinosa, Nuria
A1 Merino, Dolores
A1 Rivero-Juárez, Antonio
A1 Carrero, Ana
A1 Ríos, María José
A1 Ruiz-Morales, Josefa
A1 Gómez-Berrocal, Ana
A1 Téllez, Francisco
A1 Díaz-Menéndez, Marta
A1 Collado, Antonio
A1 Pérez-Camacho, Inés
A1 Delgado-Fernández, Marcial
A1 Vera-Méndez, Francisco
A1 Pineda, Juan A.
K1 Bilirrubina
K1 Protocolos clínicos
K1 Coinfección
K1 Hepatitis C
K1 Combinación emtricitabina, rilpivirina y tenofovir
AB Although hepatotoxicity related to antiretroviral treatment (ART) has become less frequent, hepatotoxic events,such as transaminase elevations (TE), are still a matter of concern. RPV/FTC/TDF (EPA) is a new single tablet regimen which iswidely used in real life practice. Clinical trials showed an adequate profile of liver safety in the sub-population of HIV/HCV-coinfected patients receiving rilpivirine. However, the number of individuals included in these analyses is low [1]. The aim of thisongoing study is to evaluate the incidence of TE and total bilirubin elevations (TBE) during the first 48 weeks of EPA-basedtherapy in a large population of HIV/HCV-coinfected subjects outside of clinical trials.
PB BioMed Central
YR 2014
FD 2014-11-02
LK http://hdl.handle.net/10668/2533
UL http://hdl.handle.net/10668/2533
LA en
NO Neukam K, Espinosa N, Merino D, Rivero-Juárez A, Carrero A, Ríos Mj,  et al. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study. J Int AIDS Soc.. 2014, 17(Suppl 3):19631
DS RISalud
RD Apr 4, 2025